Sareum Holdings

Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in mid-2021. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 27.5% economic interest), previously out licensed to Sierra Oncology and the de-prioritised FLT3+Aurora kinase.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Europe’s ageing buildings

Stock of the month – PZ Cussons

Q226 reflections: Leadership swings back – the value case holds

Audiovisual

Latest

The Metals Company – equity proposition

Vantage: Rockwood Strategic – UK small-cap value and active engagement

Bull, Bear & Beyond – Living REIT: executive interview

About Edison

Corporates

Investors

Careers

Sareum Holdings (AIM: SAR)

Latest Insights

Sareum Holdings — Phase II readiness draws closer

Sareum – executive interview

Sareum Holdings — Peer-reviewed validation for SDC-1801

Sareum Holdings — An important year for value creation

Market Data

Sector

Equity Analyst

Key Management

Share Price Chart

Sareum Holdings — SDC-1801 prepping to enter Phase II

Sareum Holdings — New funding extends runway to Phase II

Sareum Holdings — SDC-1801 records positive Phase Ia data

Sareum Holdings — A decisive period ahead for SDC-1801

Sareum Holdings — Positive clinical step forward in SDC-1801

Sareum Holdings — SRA737 – new partnership to kick off the year

Sareum Holdings — SDC-1801 embarks on clinical journey in FY23

Sareum Holdings — £5m funding to see SDC-1801 through Phase I

Sareum Holdings — TYKing along steadily through the clinic

Sareum Holdings — SDC-1801 on the way to the clinic

Sareum Holdings — 2023 to be a year of clinical transition

Sareum Holdings — SDC-1801 trial application refiled in Australia

Sareum Holdings — SDC-1801 CTA application hits a roadblock

Sareum Holdings — SDC-1801 poised for the clinic

Sareum Holdings — Sierra Oncology returns rights to SRA737

Sareum Holdings — Sotyktu approval positive read-across for SDC-1801

Sareum Holdings — SDC-1801 CTA filed in the UK

Sareum Holdings — GSK’s Sierra acquisition, read-across for Sareum

Sareum Holdings — Approaching the clinic

Sareum Holdings: Edison Open House Healthcare 2022

Sareum Holdings — AGM produces key highlights

Sareum Holdings — SDC-1801’s clinical plan modified

Sareum Holdings — Fund raising to cushion pipeline risk

Sareum Holdings – Edison Open House interview

Sareum Holdings — Treading the TYK2 trail

Sareum Holdings — Starting to tick the right boxes